It is illegal to post this copyrighted PDF on any website.
Brooks and Kruse


John O. Brooks III, PhD, MD^*
Jennifer L. Kruse, MD^*

^Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California
^Corresponding author: John O. Brooks III, PhD, MD (john.brooks@ucla.edu).

Published online: April 27, 2021.

Potential conflicts of interest: Dr Brooks has served on speakers bureaus for Sunovion and Janssen and has received research support from Allergan. Dr Kruse has no potential conflicts of interest to report.

Funding/support: Dr Kruse was supported in part by National Institute of Mental Health grant K23-MH116127.


To share: https://doi.org/10.4088/JCP.20lr13818

© Copyright 2021 Physicians Postgraduate Press, Inc.
Studies Support the Use of Suvorexant for the Prevention of Delirium

To the Editor: In their letter, Brooks and Kruse declare their concerns about the use of suvorexant for delirium prevention. We agree that a cohort study alone cannot provide concrete evidence to support the clinical use of a given remedy. However, we also agree that our retrospective cohort study could not establish causal relations because of non-random group assignment and lack of placebo controls. Our retrospective cohort study was based on previous randomized controlled trials (RCTs). Hatta et al. compared the delirium preventive effect between suvorexant and placebo, whereas Azuma et al. compared between suvorexant and standard treatment. Our study aimed to examine whether the results of these RCTs apply to routine clinical practice. For example, patients in these RCTs were asked to provide informed consent; therefore, patients who were comatose, had severe liver failure or respiratory disease, or were using antipsychotics or antidepressants were excluded. RCTs can examine efficacy but not effectiveness. Our retrospective cohort study provided supplementary findings for use of suvorexant to prevent delirium in routine clinical settings. We concluded that the delirium preventive effects observed in the RCTs also apply to our routine clinical practice.

We further agree that initiating suvorexant at clinical discretion can induce systematic group differences that cannot be corrected by the inclusion of covariates in the analyses, which was discussed in our article. In our study, patients in the suvorexant group were more likely to have received dexmedetomidine, haloperidol, risperidone, trazodone, and/or ramelteon before the onset of delirium. The multivariate Cox regression analysis showed no significant effect of these drugs on delirium occurrence. However, as discussed, we could not exclude the possibility that patients in the suvorexant group may have been treated for early or prodromal symptoms of delirium before receiving suvorexant. We do not claim that our retrospective study proves the effectiveness of suvorexant for delirium prevention. On the basis of previous RCTs, we examined the applicability of the efficacy proved by RCTs to everyday clinical practice. Furthermore, 2 additional cohort studies examined the delirium preventive effects of suvorexant, and 3 further cohort studies have examined the effects of suvorexant and/or ramelteon. All 5 of these studies showed delirium preventive effects of suvorexant. The results of the RCTs are consistent with these 5 cohort studies as well as our study.

We agree that the number of patients in our study was sufficient to detect an association between suvorexant and decreased rates of delirium during the first 5 days, but not throughout 30 days. In the 2,807 patients included in our study, the median intensive care unit (ICU) stay was 2 days (interquartile range, 1–4 days). Our study covered the majority of patients in ICU; however, studying more patients is necessary to determine the effectiveness of suvorexant for delirium in patients who require ICU stays of more than 5 days.

In conclusion, our study expands on the efficacy of suvorexant for delirium prevention observed in previous RCTs by showing its effectiveness in routine daily clinical practice. However, in line with the concerns of Brooks and Kruse, we must exercise caution regarding our findings until a large randomized controlled study is conducted to determine the effectiveness of suvorexant for delirium prevention, especially for non-insomniac patients.

REFERENCES


Muneto Izuwara, MD, MSc
Hisae Kihara Izuwara, MD
Reiko Tsuchie, MSc
Tomoko Araki, MSc
Tsukasa Ito, MD
Kouhei Sato, MD
Syoko Miura, MD
Koji Otsuki, MD, PhD
Michiharu Nagahama, MD
Maiko Hayashida, MD, PhD
Sadayuki Hashiooka, MD, PhD
Rei Wake, MD, PhD
Tomohiro Kimura, BSc
Shusaku Tsumoto, MD, PhD
Yoji Saito, MD, PhD
Masatoshi Inagaki, MD, PhD

© 2021 Copyright Physicians Postgraduate Press, Inc.